Collaborative Agreement, Milestone Payments

No definition available.

Name:	amrx_CollaborativeAgreementMilestonePayments
Namespace Prefix:	amrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaborative Agreement, Signing Fee

+ References

No definition available.

+ Details

Name:	amrx_CollaborativeAgreementSigningFee
Namespace Prefix:	amrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement License Revenue Agreement

+ References

No definition available.

+ Details

Name:	amrx_CollaborativeArrangementLicenseRevenueAgreement
Namespace Prefix:	amrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement, Maximum Potential Future Construction Costs

+ References

No definition available.

+ Details

Name:	amrx_CollaborativeArrangementMaximumPotentialFutureConstructionCosts
Namespace Prefix:	amrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaborative Arrangement, Term

+ References

No definition available.

+ Details

Name:	amrx_CollaborativeArrangementTerm
Namespace Prefix:	amrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative arrangement, up-front payment.

+ References

No definition available.

+ Details

Name:	amrx_CollaborativeArrangementUpfrontPayment
Namespace Prefix:	amrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

License Supply Agreement, Potential Future Milestone Payments

+ References

No definition available.

+ Details

Name:	amrx_LicenseSupplyAgreementPotentialFutureMilestonePayments
Namespace Prefix:	amrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Useful life of finite-lived intangible asset, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-5

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_TypeOfArrangementAxis=amrx_PfizerArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=amrx_LicenseAgreementWithPfizerIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=amrx_LicenseAgreementWithPfizerIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_OtherOperatingIncomeExpenseNet
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=amrx_MSNLaboratoriesPrivateLimitedSupplyAndDistributionAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=amrx_TirzepatideAdalvoLicenseAndSupplyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=amrx_DenosumabBiosimilarLicensingAndSupplyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=amrx_AlvotechHf.LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=amrx_IntasPharmaceuticalsLimitedLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Alliance and Collaboration - Narrative (Details) - USD ($) $ in Thousands				1 Months Ended	3 Months Ended		9 Months Ended
	May 26, 2026	Jan. 30, 2026	Jan. 29, 2026	Apr. 30, 2026	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025	Aug. 10, 2026	May 13, 2026
Pfizer Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement term (in years)		4 years	7 years
Pfizer Arrangement \| Pfizer Inc. (formerly Metsera, Inc.)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum potential future construction costs					$ 100,000		$ 100,000
Pfizer Inc. (formerly Metsera, Inc.) \| Location, Statement of Income, Balance [Axis]: us-gaap:OtherOperatingIncomeExpenseNet
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement license revenue agreement					0	$ 0	(6,877)	$ 0
Pfizer Inc. (formerly Metsera, Inc.) \| Location, Statement of Income, Balance [Axis]: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement license revenue agreement					$ 0	$ 245	0	$ 2,218
MSN Laboratories Private Limited Supply and Distribution Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement upfront payment				$ 75,000
Estimated useful life (in years)				5 years
Tirzepatide Adalvo License and Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License supply agreement, potential future milestone payments										$ 21,000
License supply agreement, potential future milestone payments							$ 3,000
Denosumab Biosimilar Licensing and Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Estimated useful life (in years)					5 years		5 years
Collaborative arrangement, signing fee	$ 6,000
Alvotech hf. License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License supply agreement, potential future milestone payments									$ 25,000
Intas Pharmaceuticals Limited License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License supply agreement, potential future milestone payments									$ 23,500